Your browser doesn't support javascript.
loading
Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
Kleining, Katrin; Laufenberg, Jan; Thrun, Philip; Ehlert, Dorothee; Wasem, Jürgen; Bartol, Arne.
Affiliation
  • Kleining K; Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany.
  • Laufenberg J; Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany.
  • Thrun P; Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany.
  • Ehlert D; Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany.
  • Wasem J; Institute for Health Services Management and Research, Universität Duisburg-Essen, Essen, Germany.
  • Bartol A; Essen Research Institute for Medical Management (EsFoMed) GmbH, Essen, Germany.
Health Econ Policy Law ; : 1-18, 2023 Aug 14.
Article in En | MEDLINE | ID: mdl-37577932
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Health Econ Policy Law Year: 2023 Document type: Article Affiliation country: Alemania
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Health Econ Policy Law Year: 2023 Document type: Article Affiliation country: Alemania